专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080138290A1 Fluoro-Carbon Emulsion Enhancement Agent for High Intensity Focused Ultrasound Treatment and Use thereof 审中-公开
标题翻译：用于高强度聚焦超声治疗及其应用的氟碳乳液增强剂
公开(公告)号：US20080138290A1
公开(公告)日：2008-06-12
申请号：US11794932
申请日：2005-09-02
申请人： Zhibiao Wang , Faqi Li , Ziwen Xiao , Yanbing Xiao , Liping Liu , Zhilong Wang
发明人： Zhibiao Wang , Faqi Li , Ziwen Xiao , Yanbing Xiao , Liping Liu , Zhilong Wang
IPC分类号： A61K49/22
CPC分类号： A61K41/0033 , A61K9/0009 , A61K9/0019 , A61K9/107 , A61K9/1075 , A61K31/685 , A61K49/226
摘要： The present invention discloses a fluorocarbon emulsion enhancement agent for HIFU treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a discontinuous phase comprising of a core material encapsulated by a membrane-forming material and a continuous phase comprised of aqueous medium; the discontinuous phase is uniformly dispersed in the continuous phase and the particle size of the discontinuous phase ranges from 0.1-2 μm; the amount of the membrane-forming material in the enhancement agent is 0.1-100 g/L; the core material is comprised of a liquid that undergoes a liquid-gas phase transition at 38-100° C., and the amount of the core material in the enhancement agent is 5-200 ml/L. The fluorocarbon emulsion enhancement agent for HIFU treatment of the present invention can significantly change the acoustic environment of the target location and can increase acoustic energy deposition at the target location during HIFU treatment.
摘要翻译：本发明公开了一种用于HIFU处理的碳氟化合物乳液增强剂，其可以在HIFU处理期间增加目标位置处的声能沉积。增强剂包括由膜形成材料包封的芯材料和由水性介质组成的连续相的不连续相; 不连续相均匀分散在连续相中，不连续相的粒径为0.1-2μm; 增塑剂中的成膜材料的量为0.1-100g / L; 核心材料由在38-100℃下经历液相 - 气相转变的液体组成，增强剂中核心材料的量为5-200ml / L。本发明的用于HIFU处理的碳氟化合物乳液增强剂可以显着改变目标位置的声学环境，并且可以在HIFU处理期间增加目标位置处的声能沉积。

2. 发明申请

US20080139973A1 Particle Enhancement Agent For High Intensity Focused Ultrasound Treatment And Use Thereof 审中-公开
标题翻译：用于高强度聚焦超声治疗和使用的粒子增强剂
公开(公告)号：US20080139973A1
公开(公告)日：2008-06-12
申请号：US11794931
申请日：2005-09-02
申请人： Zhibiao Wang , Faqi Li , Yanbing Xiao , Ziwen Xiao , Liping Liu , Zhilong Wang
发明人： Zhibiao Wang , Faqi Li , Yanbing Xiao , Ziwen Xiao , Liping Liu , Zhilong Wang
IPC分类号： A61N7/02
CPC分类号： A61K41/0033 , A61K9/0019 , A61K9/107 , A61K9/127 , A61K31/685
摘要： The present invention discloses a particle enhancement agent for high intensity focused ultrasound (HIFU) treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a discontinuous phase comprised of a core material encapsulated by a membrane-forming material and a continuous phase comprising of aqueous medium. The discontinuous phase is uniformly dispersed in the continuous phase and the particle size of the discontinuous phase ranges from 0.1-8 μm; the amount of the membrane-forming material in the enhancement agent is 0.1-100 g/L; the core material is comprised of a liquid that does not undergo a liquid-gas phase transition at 38-100° C., and the amount of core material in the enhancement agent is 5-200 g/L.
摘要翻译：本发明公开了一种用于高强度聚焦超声（HIFU）处理的颗粒增强剂，其可以在HIFU处理期间增加目标位置处的声能沉积。增强剂包括由膜形成材料包封的芯材料和包含水性介质的连续相组成的不连续相。不连续相均匀分散在连续相中，不连续相的粒径为0.1-8μm; 增塑剂中的成膜材料的量为0.1-100g / L; 核心材料由在38-100℃不经历液 - 气相变的液体组成，增强剂中芯材的量为5-200g / L。

3. 发明申请

US20090117052A1 Enhancement agent for high intensity focused ultrasound treatment and method for screening the same 审中-公开
标题翻译：高强度聚焦超声治疗增强剂及其筛选方法
公开(公告)号：US20090117052A1
公开(公告)日：2009-05-07
申请号：US11794928
申请日：2005-08-30
申请人： Zhibiao Wang , Faqi Li , Yanbing Xiao , Ziwen Xiao , Liping Liu , Zhilong Wang
发明人： Zhibiao Wang , Faqi Li , Yanbing Xiao , Ziwen Xiao , Liping Liu , Zhilong Wang
IPC分类号： A61B8/00 , A61N7/00
CPC分类号： A61K41/0052 , A61K41/0028
摘要： The present invention discloses an enhancement agent for high intensity focused ultrasound (HIFU) treatment, which is administered to a patient before HIFU treatment and can reduce the level of EEF at the target location to be treated with HIFU. EEF is presented by the expression: EEF=ηPt/V (unit: J/mm3), and refers to the HIFU energy needed to effectively treat a tumor per unit volume of the tumor, wherein, η=0.7; P refers to the total acoustic power of HIFU source (unit: W); t refers to the total time of HIFU treatment (unit: s); V refers to the volume of HIFU-induced lesions (unit: mm3). If the amount of EEF at the target location before administration of the enhancement agent is defined as EEF(base) and the amount of EEF at the target location after administration of the enhancement agent is defined as EEF(measurement), the ratio between EEF(base) and EEF(measurement) is more than 1, preferably more than 2, and more preferably over 4. The use of the enhancement agent for HIFU treatment of the present invention makes it possible to treat deep-seated tumors. In addition, patients with hepatic tumors can be effectively treated without removal of ribs. Accordingly, the present invention discloses methods for increasing acoustic energy deposition at target location during HIFU treatment and screening the enhancement agents for HIFU treatment.
摘要翻译：本发明公开了一种用于高强度聚焦超声（HIFU）治疗的增强剂，其在HIFU治疗之前施用于患者，并且可以降低用HIFU治疗的目标位置处的EEF水平。 EEF由以下表达式表示：EEF = etaPt / V（单位：J / mm 3），并且是指每单位体积肿瘤有效治疗肿瘤所需的HIFU能量，其中eta = 0.7; P指HIFU源的总声功率（单位：W）; t指HIFU治疗的总时间（单位：s）; V指HIFU诱导的病变体积（单位：mm3）。如果将增强剂施用前的目标位置处的EEF量定义为EEF（碱基），并且将施用增效剂后的目标位置处的EEF的量定义为EEF（测定），则EEF 碱）和EEF（测量）大于1，优选大于2，更优选超过4.使用本发明的HIFU治疗用增强剂可以治疗深层肿瘤。此外，肝脏肿瘤患者可以有效地治疗，无需排除肋骨。因此，本发明公开了在HIFU处理期间增加目标位置处的声能沉积并筛选用于HIFU处理的增强剂的方法。

4. 发明申请

US20080260790A1 Plasmid Enhancement Agent for High Intensity Focused Ultrasound Treatment and Use Thereof 审中-公开
标题翻译：用于高强度聚焦超声治疗和使用的质粒增强剂
公开(公告)号：US20080260790A1
公开(公告)日：2008-10-23
申请号：US11794927
申请日：2005-08-30
申请人： Zhibiao Wang , Faqi Li , Liping Liu , Yanbing Xiao , Ziwen Xiao , Zhilong Wang
发明人： Zhibiao Wang , Faqi Li , Liping Liu , Yanbing Xiao , Ziwen Xiao , Zhilong Wang
IPC分类号： A61K9/50 , A61K33/42 , A61K33/10 , A61P35/00
CPC分类号： A61K33/10 , A61K31/575 , A61K31/66 , A61K33/42 , A61K41/0028 , A61K41/0052 , A61K45/06 , A61N7/02 , A61K2300/00
摘要： The present invention discloses a plasmid enhancement agent for high intensity focused ultrasound (HIFU) treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a nanometer-sized biocompatible solid. The present invention also discloses another plasmid enhancement agent for HIFU treatment, wherein, the enhancement agent comprises a discontinuous phase is comprised of a core material encapsulated by a membrane-forming material, and a continuous phase comprised of aqueous medium; the discontinuous phase is uniformly dispersed in the continuous phase and has a particle size ranging from 10-1000 nm; the amount of the membrane-forming material in the enhancement agent is 0.1-100g/L; and the core material comprises nanometer-sized biocompatible solid selected from the group consisting of magnetic biomaterials, hydroxylapatite, and calcium carbonate, and the amount of the core material in the enhancement agent is 0.1-150 g/L.
摘要翻译：本发明公开了一种用于高强度聚焦超声（HIFU）处理的质粒增强剂，其可以在HIFU处理期间增加目标位置处的声能沉积。增强剂包括纳米尺寸的生物相容性固体。本发明还公开了另一种用于HIFU处理的质粒增强剂，其中增强剂包括不连续相，其包含由成膜材料包封的芯材料和由水性介质组成的连续相; 不连续相均匀分散在连续相中，粒径范围为10-1000nm; 增塑剂中的成膜材料的量为0.1-100g / L; 并且核心材料包括选自磁性生物材料，羟基磷灰石和碳酸钙的纳米尺寸的生物相容性固体，并且增强剂中的芯材料的量为0.1-150g / L。

5. 发明授权

US08653237B2 Peptide analogues 失效
标题翻译：肽类似物
公开(公告)号：US08653237B2
公开(公告)日：2014-02-18
申请号：US13481741
申请日：2012-05-25
申请人： Liping Liu , Adrian Ion Bot , David C. Diamond
发明人： Liping Liu , Adrian Ion Bot , David C. Diamond
IPC分类号： A61K38/06 , A61K38/00 , A61K51/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0008 , A61K48/00 , A61K2035/122 , A61K2039/53 , A61K2039/57 , A61K2039/645 , C07K7/06 , C07K14/47 , C07K14/70503
摘要： Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
摘要翻译：一些实施方案涉及对应于I类MHC限制性T细胞表位的肽类似物及其产生方法。这些类似物可以在与MHC分子直接相互作用的残基处含有氨基酸取代，并且可以赋予改进的，修饰的或有用的免疫学特性。此外，公开了类似物类别，其中各种取代包括非标准残基正亮氨酸和/或正缬氨酸。

6. 发明申请

US20130073163A1 ELECTRONIC PARKING BRAKE SYSTEM, ASSISTANT STARTING METHOD THEREOF FOR MOTOR VEHICLE 有权
标题翻译：电动停车制动系统，电动助力起动方法
公开(公告)号：US20130073163A1
公开(公告)日：2013-03-21
申请号：US13701812
申请日：2010-12-20
申请人： Zhaoyong Liu , Yongbin Yuan , Qindong Gu , Sheng Zhang , Liping Liu , Yulin Qiang
发明人： Zhaoyong Liu , Yongbin Yuan , Qindong Gu , Sheng Zhang , Liping Liu , Yulin Qiang
IPC分类号： B60T7/12
CPC分类号： B60T7/12 , B60T7/042 , B60W10/18 , B60W10/182 , B60W30/18027 , B60W2510/0275 , B60W2510/0638 , B60W2540/10 , B60W2540/14
摘要： An electronic parking brake system and assistant starting method thereof for a motor vehicle are provided, wherein, the electronic parking brake system receives all sensor signals and detection signals of the motor vehicle; when any one of the following conditions is satisfied, the brake will be released to assist the driver in starting: condition (1): a torque Tc transmitted by a clutch is calculated, and the calculated torque Tc transmitted by the clutch is greater than a torque needed for starting the motor vehicle; condition (2): an engine rotate speed is greater than an engine idle speed, and an accelerator pedal and a clutch pedal are depressed simultaneously; condition (3): starting trend of the motor vehicle is detected; condition (4): the detected engine rotate speed is lower than a first predetermined threshold value calculated according to a throttle opening data; condition (5): a detected rotate speed or angle of driving wheel is greater than a predetermined threshold value of rotate speed or angle. In the application of the electronic parking brake system and assistant starting method thereof for a motor vehicle, there is no need to additionally a mount clutch position sensor and a gear position sensor; according to all the available sensor signals and detection signals on the motor vehicle, the system can accurately judge whether the brake can be automatically released, and there is no need to modify the existing motor vehicle, featuring low lost and accurate judgment.
摘要翻译：提供一种用于机动车辆的电子驻车制动系统及其辅助启动方法，其中，电子驻车制动系统接收机动车辆的所有传感器信号和检测信号; 当满足以下条件之一时，制动器将被释放以帮助驾驶员起动：条件（1）：计算由离合器传递的转矩Tc，并且由离合器传递的计算转矩Tc大于启动机动车辆所需的转矩; 条件（2）：发动机转速大于发动机怠速，同时踩下油门踏板和离合器踏板; 条件（3）：检测到汽车的起动趋势; 条件（4）：检测到的发动机转速低于根据节气门开度数据计算的第一预定阈值; 条件（5）：检测到的转速或驱动轮的角度大于旋转速度或角度的预定阈值。在电动驻车制动系统的应用及其辅助启动方法中，不需要另外安装离合器位置传感器和档位传感器; 根据汽车上所有可用的传感器信号和检测信号，系统可以准确判断制动器是否可以自动释放，无需修改现有的机动车辆，具有低损失和准确的判断能力。

7. 发明授权

US08354380B2 NY-ESO-1 peptide analogs 失效
标题翻译： NY-ESO-1肽类似物
公开(公告)号：US08354380B2
公开(公告)日：2013-01-15
申请号：US11155929
申请日：2005-06-17
申请人： Liping Liu , Adrian Bot , David C. Diamond
发明人： Liping Liu , Adrian Bot , David C. Diamond
IPC分类号： C07K14/74 , C07K7/06 , C07K7/08
CPC分类号： C07K7/06 , A61K38/00 , C07K14/4748
摘要： Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
摘要翻译：一些实施方案涉及对应于I类MHC限制性T细胞表位的肽类似物及其产生方法。这些类似物可以在与MHC分子直接相互作用的残基处含有氨基酸取代，并且可以赋予改进的，修饰的或有用的免疫学特性。公开了其中各种取代包含非标准残基正亮氨酸和/或正缬氨酸的类似物类别。

8. 发明申请

US20120207238A1 METHOD AND APPARATUS FOR PROCESSING PRECODER 有权
标题翻译：用于处理预处理器的方法和装置
公开(公告)号：US20120207238A1
公开(公告)日：2012-08-16
申请号：US13502667
申请日：2010-05-12
申请人： Yuanchun Tan , Liping Liu , Xianxi Li
发明人： Yuanchun Tan , Liping Liu , Xianxi Li
IPC分类号： H04B7/06
CPC分类号： H04B7/0689 , H04B7/0404 , H04B7/0417 , H04B7/0456 , H04B7/0632 , H04B7/0639 , H04L1/0001 , H04L1/06
摘要： The present invention provides a method and an apparatus for processing a precoder. The method comprises: step A: a base station determining whether the number of received effective precoders reported by a certain UE is greater than or equal to a threshold a, if so, executing step B, otherwise, executing step D; step B: the base station determining whether each received effective precoder is according to the same number of layers, if so, executing step C, otherwise, executing step D; step C: the base station determining whether a variation speed of each effective precoder is fast, if so, applying a transmit diversity transmission mode to the UE, otherwise, applying a MIMO transmission mode to the UE; and step D: applying the MIMO transmission mode to the UE. Therefore, the present invention can reasonably predict the transmission mode and the precoder that should be employed in the transmission mode at current time for a certain UE.
摘要翻译：本发明提供了一种用于处理预编码器的方法和装置。该方法包括：步骤A：基站确定由某个UE报告的接收的有效预编码器的数量是否大于或等于阈值a，如果是，则执行步骤B，否则执行步骤D; 步骤B：基站确定每个接收到的有效预编码器是否按照相同数量的层，如果是，则执行步骤C，否则执行步骤D; 步骤C：基站确定每个有效预编码器的变化速度是否快，如果是，则向UE应用发送分集传输模式，否则，向UE应用MIMO传输模式; 步骤D：将MIMO传输模式应用于UE。因此，本发明可以合理地预测某个UE在当前时刻应当以传输模式采用的传输模式和预编码器。

9. 发明申请

US20110177047A1 METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS 有权
标题翻译：用于预防或治疗眼底疾病的方法和组合物
公开(公告)号：US20110177047A1
公开(公告)日：2011-07-21
申请号：US12861593
申请日：2010-08-23
申请人： Liping Liu , Shibo Tang , Xiaoling Liang
发明人： Liping Liu , Shibo Tang , Xiaoling Liang
IPC分类号： A61K38/07 , A61P27/02 , A61P27/12 , A61P27/06 , A61P9/10 , A61P39/06 , A61K33/04 , A61K38/13
CPC分类号： A61K38/06 , A61K38/07 , A61K45/06 , A61P27/02 , A61P27/12 , C07K5/0817 , C07K5/1016
摘要： The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
摘要翻译：本发明总体上描述了预防或治疗哺乳动物受试者的眼科疾病或病症的方法，例如糖尿病性视网膜病变，白内障，色素性视网膜炎，青光眼，黄斑变性，脉络膜新生血管形成，视网膜变性和氧诱导的视网膜病变。所述方法包括向有需要的受试者施用有效量的芳族阳离子肽。

10. 发明授权

US07951382B2 Methods for treatment of type 2 diabetes 失效
标题翻译：治疗2型糖尿病的方法
公开(公告)号：US07951382B2
公开(公告)日：2011-05-31
申请号：US12759072
申请日：2010-04-13
申请人： Cohava Gelber , Liping Liu , Zhidong Xie , Pranvera Ikonomi , John R Simms , Catherine R Auge
发明人： Cohava Gelber , Liping Liu , Zhidong Xie , Pranvera Ikonomi , John R Simms , Catherine R Auge
IPC分类号： A61K38/17
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/158
摘要： The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.
摘要翻译：本发明一般涉及与发展中的糖尿病风险增加相关的生物标志物的鉴定，以及在糖尿病诊断和预后中使用这些生物标志物的方法。本发明的生物标志物可以指示治疗的新靶标或构成用于治疗或预防糖尿病的新治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式